Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. About This ...